Clavel, Catherine M.Paunescu, EmiliaNowak-Sliwinska, PatrycjaGriffioen, Arjan W.Scopelliti, RosarioDyson, Paul J.2014-05-262014-05-262014-05-26201410.1021/jm5002748https://infoscience.epfl.ch/handle/20.500.14299/103637WOS:000335113900028A ruthenium(II)-arene complex with a perfluoroalkyl-ligand was found to display remarkable selectivity toward cancer cells. IC50 values on several cancer cell lines are in the range of 25-45 mu M, and no cytotoxic effect was observed on nontumorigenic (HEK-293) cells at concentrations up to 500 mu M (the maximum concentration tested). Consequently, this complex was used as the basis for the development of a number of related derivatives, which were screened in cancerous and noncancerous cell lines. The lead compound was then evaluated in vivo for antiangiogenic activity in the CAM model and in a xenografted ovarian carcinoma tumor (A2780) grown on the CAM. A 90% reduction in the tumor growth was observed.text::journal::journal article::research article